Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is considered a positive investment opportunity based on their continued growth in revenue, especially in their NGS segment which is expected to drive double-digit growth over the next three years. Furthermore, the company's optimization efforts and increasing ASP are expected to improve margins and cash flow. The company also has a wide range of oncology diagnostic tests and a strong position in the community channel for cancer care, making it an attractive investment opportunity.

Bears say

NeoGenomics is a clinical laboratory company with a negative outlook due to potential risks such as weaker than expected EBITDA margins, negative reimbursement changes, and potential market share loss to competitors. Additionally, the company's launch of a genomic-based malignancy profiling test is not expected for the next two years and they have not disclosed overall exposure to this market, suggesting potential challenges in this segment. This, combined with a current EV/sales multiple of ~3.0x, may result in a lower valuation and weaker financial performance for NeoGenomics in the future.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.